Top Page
MEDIROM Healthcare Technologies
(NASDAQ:MRM)
MEDIROM Healthcare Technologies (MRM) vs. SPDR S&P 500 ETF (SPY)
MEDIROM Healthcare Technologies Business Overview & Revenue Model
MEDIROM Healthcare Technologies Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 8.30B | 6.83B | 6.95B | 5.41B | 3.34B |
| Gross Profit | 2.25B | 1.57B | 1.90B | 1.42B | 428.95M |
| EBITDA | 387.50M | 310.08M | 281.02M | -276.29M | -551.16M |
| Net Income | 148.76M | 115.05M | 148.97M | -990.73M | -539.17M |
Balance Sheet | |||||
| Total Assets | 8.09B | 6.85B | 6.75B | 5.75B | 5.71B |
| Cash, Cash Equivalents and Short-Term Investments | 335.56M | 106.85M | 605.95M | 377.12M | 1.47B |
| Total Debt | 3.96B | 3.65B | 3.23B | 2.04B | 2.56B |
| Total Liabilities | 6.90B | 6.63B | 6.81B | 5.96B | 5.22B |
| Stockholders Equity | 933.27M | 210.88M | -59.38M | -208.34M | 491.26M |
Cash Flow | |||||
| Free Cash Flow | -1.90B | -767.58M | -806.44M | -652.88M | -439.98M |
| Operating Cash Flow | -1.33B | -631.74M | -685.70M | -557.23M | -366.42M |
| Investing Cash Flow | 361.39M | -328.58M | 580.44M | -83.94M | -139.60M |
| Financing Cash Flow | 1.19B | 461.21M | 340.10M | -427.95M | 1.43B |
MEDIROM Healthcare Technologies Technical Analysis
MEDIROM Healthcare Technologies Risk Analysis
MEDIROM Healthcare Technologies Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $69.13M | 0.67 | 96.56% | ― | 3.52% | 26.12% | |
61 Neutral | $18.08B | 12.82 | -1.60% | 3.03% | 1.45% | -15.68% | |
60 Neutral | $14.62M | 10.52 | 23.48% | ― | 12.93% | 66.81% | |
48 Neutral | $153.00M | 42.23 | 1.73% | ― | -37.62% | -87.69% | |
44 Neutral | $6.04M | ― | -1069.01% | ― | -6.93% | 22.70% | |
41 Neutral | $6.19M | ― | -259.91% | ― | 373.32% | 98.46% |
MEDIROM Healthcare Technologies Corporate Events
On August 28, 2025, MEDIROM Healthcare Technologies announced that its ‘REMONY for Driver’ system, developed by its subsidiary MOTHER Labs, has been certified by Japan’s Ministry of Land, Infrastructure, Transport and Tourism as a device for preventing fatigue-related driving. This certification under the governmental subsidy program allows companies to reduce costs and enhance safety measures, potentially improving MEDIROM’s market positioning in the transportation industry.
On August 22, 2025, MEDIROM Healthcare Technologies announced its involvement in the ‘World’ project, a ‘proof of human’ protocol, by installing the World ID authentication device, the ‘Orb,’ in approximately 100 Re.Ra.Ku relaxation salons. This initiative aims to provide access to a verified World ID for up to 500,000 individuals and integrate digital assets into its operations. The company plans to acquire Worldcoin tokens (WLD) and exchange up to 50% for Ethereum (ETH) as part of its financial strategy, potentially enhancing its market positioning and business expansion.
On August 20, 2025, MEDIROM Healthcare Technologies announced its Key Performance Indicators for July 2025, highlighting a total of 76,544 customers served and a high sales per customer figure of JPY 7,389, which is significantly above the industry average. The company also reported a customer repeat ratio of 77.0% and an operation ratio of 44.8%. In its health tech business, MEDIROM has expanded its Lav® app user base to 10,842 and secured contracts with 101 corporate insurance associations, reflecting its growing influence in the health guidance market.
On August 1, 2025, MEDIROM Healthcare Technologies announced its collaboration with Hakuhodo Inc. to join the ‘World’ network, a proof of human protocol for the AI era, co-founded by Sam Altman. MEDIROM plans to install the ‘Orb’ World ID authentication device in 100 Re.Ra.Ku relaxation salons by December 2025, aiming to issue 500,000 new World IDs annually. This initiative is expected to enhance MEDIROM’s market positioning by integrating cutting-edge technology into its operations, potentially increasing customer trust and engagement.
On July 21, 2025, MEDIROM Healthcare Technologies Inc. announced its Key Performance Indicators (KPIs) for June 2025, revealing a customer repeat ratio increase to 77.3% and sales per customer significantly above the industry average. The company served 77,715 customers across 304 salons, indicating robust operational performance. Additionally, the company has expanded its health tech business, with over 10,000 users of its Lav® app and contracts with 101 corporate insurance associations, highlighting its growing influence in the health guidance market.
On June 26, 2025, MEDIROM Healthcare Technologies’ board approved the issuance of stock options under its 2024 Equity Incentive Compensation Plan. These options, exercisable upon meeting specific performance criteria, aim to enhance company growth by incentivizing directors, employees, and collaborators. The stock options are set to be granted on July 18, 2025, with an exercise period from July 18, 2026, to July 17, 2030. This strategic move requires a significant revenue increase, potentially impacting the company’s market positioning and stakeholder interests.
On June 20, 2025, MEDIROM Healthcare Technologies Inc. announced its updated Key Performance Indicators (KPIs) for May 2025, highlighting improvements in its salon operations. The company served 80,631 customers, with sales per customer at ¥7,100, significantly above the industry average. The customer repeat ratio was 76.3%, and the operation ratio was 46.1%, reflecting enhanced operational efficiency. Additionally, in its health tech business, the company has expanded its Lav® app usage to over 10,000 users, partnering with 100 corporate insurance associations, indicating growth in its health guidance program.